Cresset Asset Management’s UroGen Pharma URGN Stock Holding History

Cresset Asset Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$367K	Buy	+9,966	New	+$270K	﹤0.01%	1298
2026 Q1	–	Sell	-11,216	Closed	-$263K	–	1795
2025 Q4	$263K	Sell	11,216 -5,500	-33%	-$119K	﹤0.01%	1360
2025 Q3	$333K	Hold	16,716	–	–	﹤0.01%	1199
2025 Q2	$229K	Sell	16,716 -271	-2%	-$2.6K	﹤0.01%	1246
2025 Q1	$188K	Buy	16,987 +271	+2%	+$2.89K	﹤0.01%	1540
2024 Q4	$178K	Hold	16,716	–	–	﹤0.01%	1581
2024 Q3	$212K	Hold	16,716	–	–	﹤0.01%	1959
2024 Q2	$280K	Sell	16,716 -133	-0.8%	-$1.89K	﹤0.01%	1745
2024 Q1	$253K	Buy	16,849 +133	+0.8%	+$2.17K	﹤0.01%	1665
2023 Q4	$251K	Hold	16,716	–	–	﹤0.01%	1584
2023 Q3	$234K	Sell	16,716 -477	-3%	-$7.66K	﹤0.01%	1549
2023 Q2	$178K	Buy	+17,193	New	+$190K	﹤0.01%	1757

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Cresset Asset Management's URGN Position: Q2 2026 in Review

Cresset Asset Management opened a new position in UroGen Pharma (URGN) in Q2 2026: 9,966 shares worth $367K. The stake represents ﹤0.01% of the portfolio and ranks #1298 among its holdings. This is a return to the name: Cresset Asset Management previously reported a position in URGN as recently as Q4 2025.

Cresset Asset Management first reported a position in URGN in Q2 2023 and has held it in 12 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Cresset Asset Management held 9,966 shares of UroGen Pharma worth $367K as of Q2 2026.
UroGen Pharma was a new Cresset Asset Management position in Q2 2026.
UroGen Pharma made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1298 holding.
Cresset Asset Management first reported a position in UroGen Pharma in Q2 2023 and has held it in 12 quarters since.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.